Ajanta Pharma Reports 20% Revenue Growth & 18% PAT Growth in Q3 FY 2026

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported its excellent performance for the quarter and nine months ended 31st December 2025. The company's revenue from operations for Q3 FY 2026 stood at Rs. 1,375 cr., up 20% from Q3 FY 2025. The profit after tax for the same period was Rs. 274 cr., showing a growth of 18%. The 9M FY 2026 performance highlights include a 16% increase in revenue from operations and a 14% growth in profit after tax.